Loading…
Prelude Therapeutics Incorporated is projected to rise to $5.73 by 2027, a +38% move from its current price of $4.16. PRLD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.95 | $4.16 | $4.38 | -0.02% |
| May 30 | $3.87 | $4.16 | $4.47 | -0.04% |
| May 31 | $3.80 | $4.16 | $4.54 | -0.06% |
| Jun 1 | $3.75 | $4.16 | $4.61 | -0.08% |
| Jun 2 | $3.70 | $4.16 | $4.66 | -0.10% |
| Jun 3 | $3.66 | $4.16 | $4.71 | -0.12% |
| Jun 4 | $3.63 | $4.15 | $4.76 | -0.14% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.63 | $4.15 | $4.76 | -0.14% |
| Week 2 | $3.42 | $4.15 | $5.03 | -0.28% |
| Week 3 | $3.27 | $4.14 | $5.24 | -0.42% |
| Week 4 | $3.15 | $4.14 | $5.43 | -0.55% |
| Week 5 | $3.05 | $4.13 | $5.60 | -0.69% |
| Week 6 | $2.96 | $4.13 | $5.76 | -0.83% |
| Week 7 | $2.88 | $4.12 | $5.90 | -0.97% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Prelude Therapeutics Incorporated is a clinical-stage precision oncology company focused on discovering and developing novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates.
Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Prelude Therapeutics Incorporated (PRLD) is a clinical-stage oncology company focused on precision cancer medicines. The stock is currently priced at $4.27 with a market cap of $340.09M and a rank of 3393. The current price sits near key technical levels, reflecting a small-cap, early-stage profile.
A major floor 56.5% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.7% away) — a key level to hold.
The nearest ceiling, 32.7% above — a clean break opens room to run.
A major ceiling 44.7% above — clearing it would confirm fresh momentum.
Key PRLD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PRLD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.27 | Sell | $4.24 | Sell |
| MA 10 | $4.36 | Sell | $4.35 | Sell |
| MA 20 | $4.57 | Sell | $4.42 | Sell |
| MA 50 | $4.18 | Sell | $4.13 | Buy |
| MA 100 | $3.34 | Buy | $3.53 | Buy |
| MA 200 | $2.41 | Buy | $2.82 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.07 | Neutral |
| Stoch RSI (14) | 8.99 | Buy |
| CCI (20) | -107.89 | Sell |
| Williams %R (14) | -93.40 | Info |
| MACD (12,26,9) | -0.10 | Sell |
| ROC (12) | -14.40 | Sell |
| Bollinger %B (20,2) | 0.16 | Neutral |
| Stochastic %K (14) | 6.60 | Buy |
| TRIX (15) | 0.26 | Buy |
| Awesome (5,34) | -0.28 | Sell |
| Ultimate (7,14,28) | 34.72 | Neutral |
| Momentum (10) | -0.48 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 4.14 | Buy |
| ADX (14) | 11.02 | Neutral |
| ATR (14) | 0.18 | Info |
The 30-day technical picture is bullish, with sentiment labeled BULLISH and RSI14 at 50, suggesting neutral momentum around the midpoint. The stock’s 50-day simple moving average is $4.14, above its 200-day simple moving average of $2.38, which supports a positive near-term trend. Support is at $4.27 and resistance at $5.52, while the 30-day price range runs from $3.00 to $6.09.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.81 | $4.16 | $7.04 | 0% | Neutral | |
| $4.15 | $5.73 | $8.54 | +38% | Bullish | |
| $6.19 | $9.03 | $14.28 | +117% | Bullish | |
| $7.84 | $12.01 | $19.89 | +189% | Bullish | |
| $7.80 | $12.50 | $21.52 | +200% | Bullish | |
| $7.82 | $13.06 | $23.24 | +214% | Bullish | |
| $7.79 | $13.54 | $24.81 | +225% | Bullish | |
| $9.12 | $16.46 | $30.97 | +296% | Bullish | |
| $11.81 | $22.12 | $42.64 | +432% | Bullish | |
| $13.38 | $25.97 | $51.20 | +524% | Bullish | |
| $16.54 | $36.75 | $79.40 | +783% | Bullish | |
| $40.16 | $89.24 | $205.25 | +20.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.81 | $4.16 | $4.97 | +0.00% |
| June 2026 | $3.50 | $4.19 | $5.19 | +0.66% |
| July 2026 | $3.36 | $4.09 | $5.19 | -2.44% |
| August 2026 | $3.61 | $4.45 | $5.76 | +8.95% |
| September 2026 | $3.91 | $4.87 | $6.39 | +9.29% |
| October 2026 | $3.84 | $4.82 | $6.42 | -0.84% |
| November 2026 | $3.80 | $4.83 | $6.50 | +0.04% |
| December 2026 | $4.04 | $5.16 | $7.04 | +7.02% |
Click any year to see its month-by-month PRLD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect PRLD to range from $1.81 to $7.04 through 2026. The $4.16 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The PRLD price prediction for 2027 points to an average of $5.73 (low $4.15, high $8.54) — a potential gain of +38% on today's $4.16. Momentum favours further upside here.
In 2028, PRLD is projected to trade between $6.19 and $14.28, averaging $9.03 — a potential gain of +117% from today's $4.16. That is up +58% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Prelude Therapeutics Incorporated's 2029 outlook centres on $12.01, within a $7.84 to $19.89 range. That is up +33% on the projected 2028 average. That marks a +189% change versus current levels. Momentum favours further upside here.
By 2030, PRLD could reach as high as $21.52, with a base case around $12.50 and support toward $7.80 — roughly +200% from $4.16. Buyers look set to stay in control over this stretch.
Expect PRLD to range from $7.82 to $23.24 through 2031. The $13.06 average target implies a +214% move from current prices. That is up +4% on the projected 2030 average. Momentum favours further upside here.
The PRLD price prediction for 2032 points to an average of $13.54 (low $7.79, high $24.81) — a potential gain of +225% on today's $4.16. Buyers look set to stay in control over this stretch.
In 2033, PRLD is projected to trade between $9.12 and $30.97, averaging $16.46 — a potential gain of +296% from today's $4.16. That is up +22% on the projected 2032 average. Momentum favours further upside here.
Prelude Therapeutics Incorporated's 2034 outlook centres on $22.12, within a $11.81 to $42.64 range. That is up +34% on the projected 2033 average. That marks a +432% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, PRLD could reach as high as $51.20, with a base case around $25.97 and support toward $13.38 — roughly +524% from $4.16. Momentum favours further upside here.
Expect PRLD to range from $16.54 to $79.40 through 2040. The $36.75 average target implies a +783% move from current prices. That is up +41% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The PRLD price prediction for 2050 points to an average of $89.24 (low $40.16, high $205.25) — a potential gain of +20.5x on today's $4.16. Momentum favours further upside here.
Investing $1,000 in PRLD today (≈ 240.384615 PRLD) could be worth
$21,451.45
+$20,451.45 (+2045%) by 2050 · US Dollar
Based on the average projected PRLD price of $89.24 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PRLDwould be worth at today's price.
$1,000 invested in PRLD on May 27, 2025 (≈ 1,249.999981 PRLD) would be worth
$5,200
+$4,200 (+420.0%) today · 5.20× · US Dollar
Based on a PRLD entry price of $0.8 vs. today's $4.16.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.5 | $924.44 | -7.6% |
| 1 month ago | $4.52 | $920.35 | -8.0% |
| 3 months ago | $2.87 | $1,449.48 | +44.9% |
| 6 months ago | $1.68 | $2,476.19 | +147.6% |
| 1 year ago | $0.8 | $5,200 | +420.0% |
| All time (5.0y) ago | $32.99 | $126.1 | -87.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PRLD forecast.
Our base-case forecast reaches $8.30 around 2028.
Implied market cap at $8.30: $538.81M
The multi-year forecast shows meaningful upside beyond 2026, with the 2026 avg price at $4.27 and a 2027 avg of $5.78, rising through 2028 ($9.36), 2029 ($12.50), and 2030 ($12.61). The predicted maximums rise to $22.00 by 2030, with a 2030 ROI of 195.4%. The outlook remains bullish through 2031 ($13.29), 2032 ($13.83), 2033 ($16.42), 2034 ($22.55), and 2035 ($26.51), then accelerating to 2040 ($37.28) with a 2040 max of $82.01 and a 2040 ROI of 773%, and ultimately to 2050 ($89.34) with a max of $205.48 and a 2050 ROI of 1992.2%.
These figures indicate strong upside potential, albeit with inherent uncertainty and risk typical of equities and clinical-stage biotech, and they represent projected outcomes rather than guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $12.61 with a min of $7.75 and a max of $22.00, and a projected ROI of 195.4% with bullish sentiment.
Forecasts from 2026 onward show rising averages and bullish sentiment, including 2027 avg $5.78, 2028 $9.36, 2029 $12.50, and 2030 $12.61, suggesting upside potential though not a guarantee.
Yes. The 2050 max forecast is $205.48, which exceeds $100 according to the projections.
Current price is $4.27 and market cap is $340.09M; the stock rank is 3393.
The 30-day range is from $3.00 to $6.09.
Prelude Therapeutics Incorporated Community Discussion
0Share your Prelude Therapeutics Incorporated price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.